• H2020
• Excellent Science
• Future & Emerging Technologies

Finnish company Brainshake has raised €2m in a second round of funding, following €3.5m in initial funding in July.

Combined total funding for the company during the past two years aggregates now to €7.5m. The collected equity is set to be utilised to advance regulatory approval and internationalisation of Brainshake’s blood analysis service which has provided more than 220 biomarkers from a single blood sample. Biomarkers reflect the health state of an individual and enable predicting disease risk for chronic diseases.

As a part of the €2m investment, TJP Consulting, a Finnish growth company accelerator, has joined Brainshake as a strategic partner in building the company’s global operations.

Tuomas Poskiparta, chairman of TJP Consulting said: “The disruptive power of Brainshake’s technology relies in extensive scientific background and scalability allowing the blood analysis to be used in routine healthcare.

“It’s a great opportunity to join Brainshake’s team in building the company’s global operations. Brainshake has a unique position to disrupt routine blood sample analysis globally in chronic diseases, such as diabetes and CVD.”

CEO of Brainshake, Teemu Suna, added: “Our technology has been proven by peer-reviewed science and the epidemiological studies show the power of our data in risk assessment of chronic diseases.

“Now we are bringing the technology to routine healthcare with the ultimate target to enable prevention of the world’s number one health problem.”

Brainshake’s blood analysis is already in use worldwide at leading universities.